# US 2012/0252034 A1 · Quality assays for antigen presenting cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252034 A1
- Document ID: US20120252034A1
- Status: Published application
- Kind: A1
- Application number: 13/523,814
- Filed: 2012-06-14
- Published: 2012-10-04
- Earliest claimed: 2002-05-08
- Assignees: Northwest Biotherapeutics, Inc.
- Inventors: Gopi Shankar; Patricia Anne Lodge; Alan Norman Brunelle
- Web page: https://patentgrep.com/patent/US20120252034A1

## CPC

- G01N 33/56972: {White blood cells}
- G01N 33/505: {involving T-cells}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides methods for evaluating the quality of a preparation of antigen presenting cells, such as dendritic cells. Assays for antigen-independent co-stimulation of T cells and for presentation of predetermined antigen by APCs are provided

## Claims

### Claim 1

A method for determining the quality of the antigen-independent, co-stimulatory activity of a population of antigen presenting cells (APCs), comprising:
providing allogeneic T cells having a known functional activity and being substantially free of co-stimulatory activity;
providing a sample of APCs of unknown co-stimulatory activity;
contacting the T cells with a sub-optimal concentration of an antigen-mimetic agent, wherein the antigen-mimetic consists of a CD3 binding agent that is an antibody, a plant lectin, or a mitogen;
contacting the T cells with the sample of APCs of unknown co-stimulatory activity;
determining the activation of the T cells contacted with the antigen-mimetic agent and the sample of APCs; and
comparing the determined activation of the T cells with a standard activation index for the T cells to determine the quality of the co-stimulatory activity of the population of APCs.

### Claim 2 (depends on 1)

The method of claim 1, wherein the T cells and the APCs are syngeneic.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cells and the APCs are allogenic.

### Claim 4 (depends on 1)

The method of claim 1, wherein the CD3 binding agent is anti-CD3 antibody, or an antigen binding fragment thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the APCs are dendritic cells.

### Claim 6 (depends on 5)

The method of claim 5, wherein the dendritic cells are mature dendritic cells derived from immature dendritic cells by contacting ex vivo with a dendritic cell maturation agent.

### Claim 7 (depends on 5)

The method of claim 5, wherein the dendritic cells are immature dendritic cells.

### Claim 8 (depends on 1)

The method of claim 1, wherein the T cells have been substantially depleted of peripheral blood mononuclear cells expressing CD14, CD54, CD80, CD83 or CD86 molecules on their cell surface.

### Claim 9 (depends on 1)

The method of claim 1, wherein the T cells have been substantially depleted of peripheral blood mononuclear cells expressing MHC class II molecules on their cell surface.

### Claim 10 (depends on 1)

The method of claim 1, wherein the activation of the T cells is determined by 3H-thymidine uptake assay.

### Claim 11 (depends on 1)

The method of claim 1, wherein the activation of the T cells is determined by assaying T cell cytokine production.

### Claim 12 (depends on 1)

The method of claim 1 wherein the assayed T cell cytokine production is IFNγ or Interleukin 2 production.

### Claim 13 (depends on 11)

The method of claim 11, wherein the assayed T cell cytokine production is extracellular cytokine production.

### Claim 14 (depends on 11)

The method of claim 11, wherein the assayed cytokine production is intracellular cytokine production.

### Claim 15 (depends on 1)

The method of claim 1, wherein the activation of T cells is determined by detecting the modulation of expression of a T cell activation marker.

### Claim 16 (depends on 15)

The method of claim 15, wherein the T cell activation marker is CD25, CD69, CD44 or CD125.

### Claim 17 (depends on 15)

The method of claim 15, wherein the T cell activation marker is detected using labeled antibody capable of binding to the T cell activation marker.

### Claim 18 (depends on 1)

The method of claim 1, wherein comparing the determined activation with the standard activation index includes comparing the determined T cell activation with activation of the T cells contacted with the sample of dendritic cells alone to determine the quality of the dendritic cells.

### Claim 19 (depends on 1)

The method of claim 1, wherein the standard activation index is a threshold value.

### Claim 20 (depends on 1)

The method of claim 1, wherein the standard activation index is a range of values, each value associated with a predetermined quality of dendritic cells.

### Claim 21 (depends on 1)

The method of claim 1, further comprising determining presentation of a predetermined antigen by the APCs.

### Claim 22 (depends on 21)

The method of claim 21, wherein presentation of the predetermined antigen is determined by Western blotting, flow cytometry or activation of antigen-specific T cells.

### Claim 23

A method for determining the quality of the antigen-independent co-stimulatory activity of a preparation of dendritic cells, comprising:
contacting a first quantity of T cells, which are substantially free of co-stimulatory activity and have a known functional activity, with a suboptimal quantity of an antigen-mimetic agent, wherein the antigen-mimetic consists of a CD3 binding agent that is an anti-CD3 antibody, a plant lectin, or a mitogen, and with a first sample of a dendritic cell preparation of unknown co-stimulatory activity;
determining a first activation value for the first quantity of T cells;
contacting a second quantity of T cells with a second sample of the dendritic cell preparation or the suboptimal quantity of the antigen-mimetic agent;
determining a second activation value for the second quantity of T cells; and
comparing the first and second activation values to determine the quality of the co-stimulatory activity of the dendritic cell preparation.

### Claim 24 (depends on 23)

The method of claim 23, wherein the T cells are allogenic with respect to the dendritic cell preparation.

### Claim 25 (depends on 23)

The method of claim 23, wherein the T cells are syngeneic with respect to the dendritic cell preparation.

### Claim 26 (depends on 23)

The method of claim 23, further comprising determining presentation of a predetermined antigen by the dendritic cells.

### Claim 27 (depends on 26)

The method of claim 26, wherein presentation of the predetermined antigen is determined by Western blotting, flow cytometry or activation of antigen-specific T cells.

### Claim 28

A method for determining the quality of a preparation of dendritic cells, comprising:
(1) providing a dendrite cell preparation of unknown co-stimulatory activity and unknown antigen presenting ability for a predetermined antigen;
(2) determining the co-stimulatory activity of the dendritic cell preparation, said determination of co-stimulatory activity comprising
(a) providing allogeneic T cells of known functional activity and substantially free of co-stimulatory activity;
(b) contacting the T cells with a suboptimal quantity of an antigen-mimetic agent, wherein the antigen-mimetic is a CD3 binding agent consisting of an anti-CD3 antibody, or an antigen binding fragment thereof, a plant lectin, or a mitogen, and with a first sample of the dendritic cell preparation;
(c) determining the activation of the contacted allogeneic T cells; and
(d) comparing the determined activity of the contacted T cells with the standard activation index for the T cells to the determined co-stimulatory activity of the dendritic cell preparation;
(3) determining presentation of the predetermined antigen by the preparation of dendritic cells, said determination of presentation comprising:
(a) contacting a second sample of the dendritic cell preparation with the predetermined antigen; and
(b) determining the amount of predetermined antigen presented by the dendritic, cells; and
(4) determining the quality of the dendritic cell preparation used on the determined co-stimulatory activity and determined antigen-specific presentation of the predetermined antigen.

### Claim 29 (depends on 28)

The method of claim 28, wherein the antigen-mimetic agent is a CD3 binding agent, a plant lectin or a mitogen.

### Claim 30 (depends on 28)

The method of claim 28, wherein the dendritic cells are mature dendritic cells derived from immature dendritic cells by contacting ex vivo with a maturation agent.

### Claim 31 (depends on 28)

The method of claim 28, wherein the dendritic cells are immature dendritic cells.

### Claim 32 (depends on 28)

The method of claim 28, wherein the T cells have been substantially depleted of peripheral blood mononuclear cells expressing MHC Class II, CD14, CD54, CD80, CD83 or CD86 molecules on their cell surface.

### Claim 33 (depends on 28)

The method of claim 28, wherein the activation of the T cells is determined by 3 H-thymidine proliferation assay.

### Claim 34 (depends on 28)

The method of claim 28, wherein the activation of the cells is determined by assaying T cell cytokine production.

### Claim 35 (depends on 34)

The method of claim 34, wherein the T cell cytokine production is IFNγ or Interleukin 2 production.

### Claim 36 (depends on 34)

The method of claim 34, wherein the T cell cytokine production is extracellular cytokine production.

### Claim 37 (depends on 34)

The method of claim 34, wherein the T cell cytokine production is intracellular cytokine production.

### Claim 38 (depends on 28)

The method of claim 28, wherein the activation of T cells is determined by expression of at least one T cell activation marker.

### Claim 39 (depends on 38)

The method of claim 38, wherein the T cell activation marker is CD25, CD69, CD44 or CD125.

### Claim 40 (depends on 38)

The method of claim 38, wherein the T cell activation marker is detected using labeled antibody capable of binding to the T cell activation marker.

### Claim 41 (depends on 28)

The method of claim 28, wherein determining the co-stimulatory activity includes comparison of the determined T cell activation with a standard activation index far the T cells.

### Claim 42 (depends on 41)

The method of claim 41, wherein the standard activation index is a threshold value.

### Claim 43 (depends on 41)

The method of claim 41 wherein the standard activation index is range of values, the values associated with different predetermined co-stimulatory activities.

### Claim 44 (depends on 28)

The method of claim 28, wherein presentation of the predetermined antigen is determined by Western blotting, flow cytometry or activation of antigen-specific T cells.
